Estrogen Receptor β Activates the Human Retinoic Acid Receptorα -1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Human estrogen receptor-α (hERα) or -β (hERβ) transfected into Hep G2 or COS1 cells each responded to estrogen to increase transcription from an estrogen-responsive element (ERE)-driven reporter vector with similar fold induction through a classical mechanism involving direct receptor binding to DNA. ER antagonists inhibited this estrogen induction through both hERα and hERβ, although raloxifene was more potent through ERα than ERβ, and tamoxifen was more potent via ERβ than ERα. We have shown previously that estrogen stimulated the human retinoic acid receptor-α-1 (hRARα-1) promoter through nonclassical EREs by a mechanism that was ERα dependent, but that did not involve direct receptor binding to DNA. We show here that in contrast to hERα, hERβ did not induce reporter activity driven by the hRARα-1 promoter in the presence of estrogen. While hERβ did not confer estrogen responsiveness on this promoter, it did elicit transcriptional activation in the presence of 4-hydroxytamoxifen (4-OH-Tam). Additionally, this 4-OH-Tam agonist activity via ERβ was completely blocked by estrogen. Like ERα, transcriptional activation of this promoter by ERβ was not mediated by direct receptor binding to DNA. While hERα was shown to act through two estrogen-responsive sequences within the promoter, hERβ acted only at the 3′-region, through two Sp1 sites, in response to 4-OH-Tam. Other ER antagonists including raloxifene, ICI-164,384 and ICI-182,780 also acted as agonists through ERβ via the hRARα-1 promoter. Through the use of mutant and chimeric receptors, it was shown that the 4-OH-Tam activity via ERβ from the hRARα-1 promoter in Hep G2 cells required the amino-terminal region of ERβ, a region that was not necessary for estrogen-induced ERβ activity from an ERE in Hep G2 cells. Additionally, the progesterone receptor (PR) antagonist RU486 acted as a weak (IC50 >1 μm) antagonist via hERα and as a fairly potent (IC50 ∼200 nm) antagonist via hERβ from an ERE-driven reporter in cells that do not express PR. Although RU486 bound only weakly to ERα or ERβ in vitro, it did bind to ERβ in whole-cell binding assays, and therefore, it is likely metabolized to an ERβ-interacting compound in the cell. Interestingly, RU486 acted as an agonist through ERβ to stimulate the hRARα-1 promoter in Hep G2 cells. These findings may have ramifications in breast cancer treatment regimens utilizing tamoxifen or other ER antagonists and may explain some of the known estrogenic or antiestrogenic biological actions of RU486.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ERβ: Identification and characterization of a novel human estrogen receptor
Mosselman, S., Polman, J., & Dijkema, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00782-x · Cited by 2,269
Cited by
Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., & Gustafsson, J.-Å. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 1,996
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Björnström, L., & Sjöberg, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0486 · Cited by 1,362
Role of Estrogen Receptor Beta in Estrogen Action
Pettersson, K., & Gustafsson, J.-Å. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.165 · Cited by 491
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J.-Å., & Safe, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5379 · Cited by 401
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Webb, P. M., Nguyen, P. T., Valentine, C. D., Lopez, G. N., Kwok, G. R., McInerney, E. M., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J.-Α., Nilsson, S. V., et al. (1999) · Molecular Endocrinology · doi:10.1210/me.13.10.1672 · Cited by 396
Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi002 · Cited by 310
Estrogen Receptor β: An Overview and Update
Zhao, C., Dahlman-Wright, K., & Gustafsson, J.-Å. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06003 · Cited by 309
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
Vasudevan, N., Ogawa, S., & Pfaff, D. (2002) · Physiological Reviews · doi:10.1152/physrev.00014.2002 · Cited by 129
Buwalda, B., & Schagen, S. B. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.12.012 · Cited by 43
Metadata
- Authors
- Zou, A., Marschke, K. B., Arnold, K. E., Berger, E. M., Fitzgerald, P., Mais, D. E., & Allegretto, E. A.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1999-03-01
- Volume
- 13
- Issue
- 3
- Pages
- 418-430
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2065705165
- Cited by
- 103
- References
- 1
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.